OBJECTIVES: The aim is to review genes aberrantly methylated in pancreatic cancer. This review focuses on DNA promoter hypermethylation in plasma and serum to describe the most promising genes that may be useful as minimally invasive diagnostic blood-based markers for pancreatic cancer. METHODS: A systematic search of the literature was performed using the PubMed and EMBASE databases. The following MeSH terms and free text were used: pancreatic disease, pancreatic cancer, pancreatic neoplasm, methylation, DNA hypermethylation, CG rich sequence, CpG island, cell-free DNA, blood, plasma, serum, fluids, and secretions. RESULTS: In total, 720 articles were found. Eight studies on cell-free DNA promoter hypermethylation in plasma or serum and 2 studies on hypermethylation in whole blood/leukocyte DNA from patients with pancreatic cancer were identified. The search for a hypermethylated marker in cell-free DNA is characterized by a few small studies lacking well-defined control groups. No single gene has been identified as a diagnostic marker. CONCLUSION: Because of insufficient power, none of the genes examined have the potential to work as an individual diagnostic marker, suggesting that a panel of several genes is needed. Further research is warranted before a blood-based diagnostic marker for pancreatic cancer based on promoter hypermethylation can be applied clinically.
OBJECTIVES: The aim is to review genes aberrantly methylated in pancreatic cancer. This review focuses on DNA promoter hypermethylation in plasma and serum to describe the most promising genes that may be useful as minimally invasive diagnostic blood-based markers for pancreatic cancer. METHODS: A systematic search of the literature was performed using the PubMed and EMBASE databases. The following MeSH terms and free text were used: pancreatic disease, pancreatic cancer, pancreatic neoplasm, methylation, DNA hypermethylation, CG rich sequence, CpG island, cell-free DNA, blood, plasma, serum, fluids, and secretions. RESULTS: In total, 720 articles were found. Eight studies on cell-free DNA promoter hypermethylation in plasma or serum and 2 studies on hypermethylation in whole blood/leukocyte DNA from patients with pancreatic cancer were identified. The search for a hypermethylated marker in cell-free DNA is characterized by a few small studies lacking well-defined control groups. No single gene has been identified as a diagnostic marker. CONCLUSION: Because of insufficient power, none of the genes examined have the potential to work as an individual diagnostic marker, suggesting that a panel of several genes is needed. Further research is warranted before a blood-based diagnostic marker for pancreatic cancer based on promoter hypermethylation can be applied clinically.
Authors: Shounak Majumder; William R Taylor; Patrick H Foote; Calise K Berger; Chung Wah Wu; Douglas W Mahoney; William R Bamlet; Kelli N Burger; Neil Postier; Jaime de la Fuente; Karen A Doering; Graham P Lidgard; Hatim T Allawi; Gloria M Petersen; Suresh T Chari; David A Ahlquist; John B Kisiel Journal: Clin Cancer Res Date: 2021-02-16 Impact factor: 13.801
Authors: Sona Ciernikova; Julie Earl; María Laura García Bermejo; Viola Stevurkova; Alfredo Carrato; Bozena Smolkova Journal: Int J Mol Sci Date: 2020-06-08 Impact factor: 5.923
Authors: Stine Dam Henriksen; Poul Henning Madsen; Anders Christian Larsen; Martin Berg Johansen; Inge Søkilde Pedersen; Henrik Krarup; Ole Thorlacius-Ussing Journal: Oncotarget Date: 2017-09-30
Authors: Sarah Schott; Rongxi Yang; Sarah Stöcker; Federico Canzian; Nathalia Giese; Peter Bugert; Frank Bergmann; Oliver Strobel; Thilo Hackert; Christof Sohn; Barbara Burwinkel Journal: Oncotarget Date: 2017-06-27
Authors: Iván A González; Liang-I Kang; Gregory A Williams; Jingxia Liu; David G DeNardo; William G Hawkins; Deyali Chatterjee Journal: Am J Surg Pathol Date: 2020-06 Impact factor: 6.298